Study to Demonstrate the Lot-to-lot Consistency and to Evaluate the Safety of an Adjuvanted Influenza Vaccine Candidate

GSK Investigational Site, Hamar

GSK Investigational Site, Elverum

GSK Investigational Site, Stavanger

GSK Investigational Site, Paradis

GSK Investigational Site, Athens

GSK Investigational Site, Caen

GSK Investigational Site, Ketzin

GSK Investigational Site, Papagos/Athens

GSK Investigational Site, Lagord

GSK Investigational Site, Tostedt

GSK Investigational Site, Bad Bramstedt

GSK Investigational Site, Toulouse

GSK Investigational Site, Montpellier

GSK Investigational Site, Koenigslutter

GSK Investigational Site, Gières

GSK Investigational Site, Wolmirstedt

GSK Investigational Site, Tartu

GSK Investigational Site, Thessaloniki

GSK Investigational Site, Lille

GSK Investigational Site, Paris

GSK Investigational Site, Rouen

GSK Investigational Site, Oberaudorf

GSK Investigational Site, Haag

GSK Investigational Site, Marktl

GSK Investigational Site, Höhenkirchen-Siegertsbrunn

GSK Investigational Site, Poitiers

GSK Investigational Site, Saratov

GSK Investigational Site, Kazan'

GSK Investigational Site, Yekaterinburg

GSK Investigational Site, Delitzsch

GSK Investigational Site, Freital

GSK Investigational Site, Kamenz

GSK Investigational Site, Pirna

GSK Investigational Site, Weißenberg

GSK Investigational Site, Goudi / Athens

GSK Investigational Site, Haidari

GSK Investigational Site, Marousi

GSK Investigational Site, Nikaia Piraeus

GSK Investigational Site, Orestiáda

GSK Investigational Site, Reading

GSK Investigational Site, Cardiff

GSK Investigational Site, Glasgow

GSK Investigational Site, Buckshaw Village, Chorley

GSK Investigational Site, Edgbaston, Birmingham

GSK Investigational Site, Manchester

GSK Investigational Site, Waterloo, Liverpool